Physician Education · Interventional & Preventive Cardiology

The 2026 ACC Antiplatelet Statement: A Field Guide to Balancing Ischemia and Bleeding

What changed, what stayed the same, and what it costs — a high-yield synthesis for the practicing cardiologist.

The 2026 ACC Scientific Statement on antiplatelet therapy pulls together a decade of fragmented guidance into one document spanning primary prevention, acute coronary syndrome (ACS), peripheral artery disease (PAD), stroke, valve disease, and perioperative care.

Its central theme is not a single new drug but a philosophy: match antiplatelet intensity to a patient's ischemic risk trajectory, then de-escalate as that risk falls and bleeding risk does not.

Below is the condensed, point-of-care version.

Primary Prevention: Aspirin's Shrinking Lane

Aspirin remains the cheapest and most widely used antiplatelet available, but the statement is blunt about its limits in primary prevention.

A pooled meta-analysis of 13 trials and over 165,000 participants found a modest 11% relative reduction in cardiovascular events (HR 0.89) but a 43% relative increase in major bleeding.

The number needed to treat to prevent one event was 241, against a number needed to harm of 880 for intracranial hemorrhage specifically.

The statement's practical rule: consider low-dose aspirin only in adults aged 40–70 with elevated ischemic risk and low bleeding risk, and avoid routine use after age 70.

Coronary artery calcium scoring helps sharpen that decision, with scores ≥100–400 identifying patients most likely to see net benefit.

Aspirin for Primary Prevention — Benefit vs. Harm (per 1,000 patient-years)

Choosing and Timing DAPT After ACS or PCI

For patients with ACS undergoing percutaneous coronary intervention (PCI), the statement favors prasugrel or ticagrelor over clopidogrel as the default P2Y12 inhibitor, based on the PLATO and TRITON-TIMI 38 trials.

Clopidogrel is preferred instead in patients over 75, given a higher bleeding risk with the more potent agents in that age group.

Default dual antiplatelet therapy (DAPT) duration is 12 months for ACS and 6 months for chronic coronary disease, with aspirin continued throughout the peri-PCI period.

A cluster of trials — TWILIGHT, TICO, and T-PASS — showed that dropping aspirin after 1–3 months and continuing the P2Y12 inhibitor alone cuts bleeding without a rise in ischemic events, but this evidence base applies mainly to ticagrelor, not clopidogrel.

Unguided de-escalation from ticagrelor or prasugrel down to clopidogrel at 1 month is a reasonable option in selected lower-risk patients who prioritize bleeding reduction.

Setting	Default DAPT Duration	Early De-escalation Option
ACS + PCI	12 months (aspirin + prasugrel/ticagrelor)	P2Y12 monotherapy at 1–3 mo (ticagrelor best supported)
Chronic coronary disease + PCI	6 months (aspirin + clopidogrel)	P2Y12 monotherapy at 1–3 mo in selected patients
PAD, post-revascularization	1–6 months	Single antiplatelet + low-dose rivaroxaban long term
Minor stroke / high-risk TIA	21 days (aspirin + clopidogrel)	Antiplatelet monotherapy thereafter
CABG	Aspirin monotherapy is standard	DAPT lowers vein-graft failure only, at a bleeding cost

Case Vignette

A 68-year-old with a non-ST-elevation MI undergoes PCI with a drug-eluting stent and is discharged on aspirin plus ticagrelor.

At the 1-month visit she reports easy bruising and asks whether she really needs two blood thinners for a full year.

Using the statement's framework, her interventional cardiologist checks her ARC-HBR criteria, finds none met, and offers a evidence-based option: continue ticagrelor and drop aspirin now, per the TWILIGHT and TICO data, since her ischemic risk has already fallen substantially past the first month.

Long-Term Therapy Beyond One Year

Past the first year after ACS, the statement highlights emerging data that clopidogrel monotherapy may outperform aspirin monotherapy for secondary prevention, with similar or lower bleeding, based on HOST-EXAM 10-year follow-up and SMART-CHOICE 3.

For very high-risk patients with stable coronary or peripheral artery disease, adding low-dose rivaroxaban 2.5 mg twice daily to aspirin 81 mg daily is a reasonable long-term option, based on the COMPASS trial's reduction in MACE and total mortality.

This "vascular dose" strategy is not appropriate for anyone with a prior stroke or major bleeding history.

Special Populations in Brief

In PAD, shorter DAPT courses (1–6 months) are typical after revascularization, and low-dose rivaroxaban added to aspirin reduces both major cardiac and major limb events per VOYAGER-PAD.

In minor ischemic stroke or high-risk TIA, DAPT with aspirin and clopidogrel for 21 days beats aspirin alone for reducing recurrent stroke, after which therapy steps back down to monotherapy.

Triple therapy combining an anticoagulant with dual antiplatelets should be avoided; the default after PCI in a patient needing oral anticoagulation is a short aspirin run-in followed by an anticoagulant plus clopidogrel.

Patients with a bioprosthetic aortic or mitral valve typically do fine on single antiplatelet therapy (low-dose aspirin) long term, with no added benefit from routine DAPT or anticoagulation.

Ischemic vs. Bleeding Risk Over Time After an Acute Event

Monitoring, Interactions, and Adherence

CYP2C19 loss-of-function alleles reduce clopidogrel's active metabolite and raise thrombotic risk after PCI, though routine genotyping remains optional rather than mandated.

Concomitant omeprazole theoretically blunts clopidogrel's antiplatelet effect via shared CYP2C19 metabolism, but randomized data show no increase in ischemic events, so proton pump inhibitors are still recommended in patients at high bleeding risk.

Cost is a major driver of nonadherence: roughly one in four low-income families with ASCVD faces significant financial burden from medication costs, and early discontinuation of DAPT after MI raises the risk of stent thrombosis.

Generic clopidogrel is the cheapest option, generic ticagrelor and prasugrel are now increasingly available, and dose reduction of ticagrelor to 60 mg twice daily after the acute phase cuts nonadherence driven by bleeding and dyspnea without losing efficacy.

Drug and Device Reference Table

Agent	Class	Approx. Monthly Cost (generic, GoodRx)	Maker (Ticker)
Clopidogrel (Plavix)	P2Y12 inhibitor	$5–$10	Originator Sanofi SNY
Ticagrelor (Brilinta)	P2Y12 inhibitor	$23–$35 (generic); brand ~$460+	AstraZeneca AZN
Prasugrel (Effient)	P2Y12 inhibitor	$14–$20	Daiichi Sankyo / Eli Lilly LLY
Rivaroxaban 2.5 mg (Xarelto)	Factor Xa inhibitor, "vascular dose"	~$37–$45 (generic 2.5 mg)	Johnson & Johnson/Janssen JNJ; co-marketed by Bayer
Aspirin, low dose	COX-1 inhibitor	Under $5	Multiple generic manufacturers

Bottom Line

Antiplatelet strategy in 2026 is a moving target that shifts with time-since-event, not a fixed prescription written at discharge.

Start intensively when ischemic risk is highest, reassess bleeding risk at every visit using tools like ARC-HBR, and be willing to de-escalate once the first month or two has passed — especially with ticagrelor, where the evidence for early aspirin withdrawal is strongest.

Cost and adherence deserve the same attention as pharmacology, since a cheaper regimen a patient actually takes beats an optimal one they abandon.

References

1. American College of Cardiology. Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease: 2026 ACC Scientific Statement. J Am Coll Cardiol. 2026.
2. Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI (TWILIGHT). N Engl J Med. 2019;381:2032-2042.
3. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease (COMPASS). N Engl J Med. 2017;377:1319-1330.
4. Kang J, Park S, Yang H-M, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after PCI: 10-year follow-up of HOST-EXAM. Lancet. 2026;407:1439-1447.
5. Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019;321:277-287.

Clinical disclaimer: This article summarizes a scientific statement for physician education and is not a substitute for individualized clinical judgment or the full guideline text. Financial disclaimer: Ticker and pricing information is for general reference only, is not investment advice, and changes frequently; consult a licensed financial advisor and current pharmacy sources before making decisions.

Prevention & Nutrition · Cardiometabolic Risk

The Inflamed Artery, The Inflamed Brain: What a New Dementia Study Means for Cardiology Practice

A 15-year Swedish cohort links a lower-inflammatory diet to reduced dementia risk even in patients with Alzheimer biomarkers — and the biology it points to is one cardiologists already know well.

Physician Education & Investor Briefing · Cardiovascular & Cognitive Health

A newly published cohort study in JAMA Network Open followed 1,865 dementia-free older adults for up to 15 years and found that a dietary pattern with lower inflammatory potential was tied to meaningfully lower dementia risk.

The signal held even among participants whose blood already showed elevated Alzheimer disease biomarkers, a population cardiologists increasingly encounter given the overlap between vascular risk factors and neurodegeneration.

For a specialty that has spent the last decade testing whether targeting vascular inflammation can prevent heart attacks and strokes, this study is a reminder that the same inflammatory biology may also be shaping the brain.

Here is what the data show, why the mechanism should feel familiar, and how it might inform the conversations cardiologists are already having about diet, statins, and anti-inflammatory cardiovascular therapy.

What the Study Found

Investigators from the Karolinska Institutet's Aging Research Center analyzed the Swedish National Study on Aging and Care in Kungsholmen, enrolling adults 60 and older and following them for a mean of 8.4 years.

Diet quality was scored three ways: the Alternate Mediterranean Diet, the Alternative Healthy Eating Index, and a reversed Empirical Dietary Inflammatory Index, with the last one specifically capturing inflammatory potential.

Participants were stratified by three blood biomarkers: p-tau217 (an Alzheimer pathology marker), neurofilament light chain (a marker of neuronal injury), and glial fibrillary acidic protein (a marker of glial activation).

Among people with elevated biomarker levels, only the lower-inflammatory diet pattern showed a consistent inverse association with dementia risk, while the Mediterranean and healthy-eating indices mattered most in people with lower biomarker levels.

Dementia Risk Reduction per 1-SD Increase in Anti-Inflammatory Diet Adherence, by Biomarker Status

Elevated p-tau217

29% lower

Elevated GFAP

27% lower

Elevated NfL

21% lower

Hazard ratio reductions for all-cause dementia associated with each 1-z-score increase in adherence to the reversed Empirical Dietary Inflammatory Index (rEDII), among participants with elevated biomarker levels.

Biomarker	What it reflects	HR with higher anti-inflammatory diet adherence
p-tau217	Alzheimer-specific tau pathology	0.71 (95% CI, 0.58–0.88)
Neurofilament light chain (NfL)	Nonspecific neuronal injury	0.79 (95% CI, 0.66–0.95)
GFAP	Glial/astrocyte activation	0.73 (95% CI, 0.60–0.89)

Source: Mrhar et al, JAMA Network Open, 2026.

Why This Overlaps With Cardiology

Baseline data from the study are notable to any cardiologist: participants with elevated p-tau217 had roughly double the rate of heart disease, hypertension, and chronic kidney disease compared with those who had lower biomarker levels.

This is consistent with a growing body of work suggesting that cardiovascular risk factors and neurodegeneration share upstream inflammatory pathways rather than being purely coincidental comorbidities.

Cardiology has already run the largest real-world experiment on this idea through the CANTOS trial, which tested whether directly neutralizing interleukin-1β with canakinumab could lower cardiovascular events independent of LDL cholesterol.

Canakinumab, marketed as Ilaris by NovartisNVS, produced a modest but statistically significant reduction in recurrent cardiovascular events, validating inflammation as a target distinct from lipids.

The more clinically relevant descendant of that hypothesis is low-dose colchicine, now FDA-approved as a dedicated cardiovascular anti-inflammatory under the brand Lodoco.

In the pivotal LoDoCo2 trial program, the 0.5 mg dose reduced major cardiovascular events with an absolute risk reduction of roughly 2.8% over the study period.

Lodoco is made by privately held Agepha Pharma, so it carries no public ticker, but it is priced around $393 for 30 tablets with a GoodRx coupon, against a retail price near $635.

Statins remain the most widely used anti-inflammatory-adjacent cardiovascular therapy, since they lower high-sensitivity CRP as well as LDL, and generic atorvastatin now costs as little as roughly $10 to $16 for a 30-day supply.

Anti-Inflammatory Cardiovascular Pharmacotherapy at a Glance

Agent	Brand	Company (Ticker)	Approx. cash price	CV role
Canakinumab	Ilaris	Novartis (NVS)	Specialty pricing, not routinely used for CVD	IL-1β inhibition; proof-of-concept for inflammatory hypothesis
Colchicine 0.5 mg	Lodoco	Agepha Pharma (private)	~$393/30 tablets (GoodRx)	FDA-approved to reduce MI, stroke, revascularization, CV death
Atorvastatin	Lipitor (generic widely used)	Pfizer (PFE)	~$10–$16/30 tablets (GoodRx)	LDL lowering plus CRP/inflammatory reduction

Pricing reflects publicly listed GoodRx cash prices at the time of writing and may vary by pharmacy, region, and insurance coverage.

Chronic low-grade
systemic inflammation

→

Vascular endothelial
injury & atherosclerosis

→

Neuroinflammation &
accelerated cognitive decline

What "Anti-Inflammatory Diet" Actually Means

There is no single certified anti-inflammatory diet; instead, the term describes an eating pattern that scores well on indices tracking foods linked to lower systemic inflammatory markers such as interleukin-6 and CRP.

In practice, this overlaps substantially with the Mediterranean-style pattern already recommended for cardiovascular risk reduction, making it an easy message to reinforce during routine visits.

Favor	Limit
Vegetables, fruits, legumes, nuts	Sugar-sweetened beverages
Whole grains, olive oil, fatty fish	Ultraprocessed snack foods
Coffee and tea in moderation	Red and processed meats

Practical Takeaways for the Cardiology Visit

This is an observational study and cannot prove that diet prevents dementia, so counseling should be framed as one modifiable piece of a larger risk picture rather than a guaranteed intervention.

Patients already being counseled on Mediterranean-pattern eating for lipid or blood pressure management are, in effect, already receiving dietary advice aligned with this dementia-risk signal.

For patients on colchicine or intensive statin therapy for residual inflammatory risk, this study offers an additional talking point about the shared biology of vascular and cognitive aging.

Routine cognitive screening remains reasonable in older patients with heavy vascular risk burden, independent of this study, given the well-established overlap between vascular disease and dementia risk.

Case Vignette

A 74-year-old with hypertension, type 2 diabetes, and prior non-ST-elevation myocardial infarction is seen for a routine follow-up on high-intensity statin therapy and low-dose colchicine.

The patient's daughter mentions a family history of Alzheimer disease and asks whether "anti-inflammatory eating" could help protect her father's memory as well as his heart.

This is an opportunity to reinforce the Mediterranean-pattern dietary counseling already underway for cardiovascular risk, note the plausible shared inflammatory mechanism with cognitive decline, and manage expectations about the observational, non-causal nature of the diet-dementia evidence.

Bottom Line

A large Swedish cohort study found that a lower-inflammatory diet was associated with roughly 21–29% lower dementia risk even in older adults with elevated Alzheimer-related blood biomarkers.

The finding strengthens the case for dietary counseling that cardiologists already deliver for vascular risk reduction, and it dovetails with a decade of cardiovascular research validating inflammation, independent of lipids, as a legitimate therapeutic target.

No causal claim can be made from observational data, and no dietary supplement or single food replaces guideline-directed lipid, blood pressure, and glycemic control for either cardiovascular or cognitive risk reduction.

References

1. Diet Quality and Dementia Risk in Older Adults With Alzheimer Pathology, JAMA Network Open, June 25, 2026.
2. Healthier diet linked to lower dementia in older adults at risk, Karolinska Institutet News.
3. Canakinumab and cardiovascular outcomes: results of the CANTOS trial, PMC.
4. LODOCO (colchicine) Full Prescribing Information, FDA.
5. LODOCO Healthcare Provider Resources, Agepha Pharma.
6. Lodoco Prices, Coupons and Savings Tips, GoodRx.

Clinical & Financial Disclaimer This article is intended for physician education and summarizes published research; it is not individualized medical advice and should not replace clinical judgment or guideline-directed care. Ticker symbols, pricing, and company information are provided for educational context only and do not constitute investment advice or a recommendation to buy or sell any security; drug prices are approximate, change frequently, and vary by pharmacy, insurer, and location.

Clinical Cardiology · Heart Failure

The Second Universal Definition of Heart Failure: What Changes for Practice

A new joint consensus retires rigid ejection-fraction cutoffs, expands how clinicians classify the causes of heart failure, and reframes the syndrome as a dynamic rather than fixed diagnosis.

9-minute read · Physician education · Includes physician-investor context

A joint writing group representing the American Heart Association, the American College of Cardiology, the European Society of Cardiology, and the World Heart Federation has published the Second Universal Definition of Heart Failure.

The document updates and reaffirms the first universal definition published in 2021, which introduced pre-heart failure as stage B and standardized previously ambiguous terminology.

It is not a clinical practice guideline, but a shared vocabulary intended to align trials, registries, and day-to-day documentation across specialties.

For a cardiologist writing notes, coding encounters, or screening for enrollment eligibility, the changes are practical rather than theoretical.

Why the Ejection-Fraction Cutoffs Had to Go

The first universal definition relied on specific left ventricular ejection fraction thresholds to separate HF with reduced ejection fraction from HF with preserved ejection fraction.

The writing committee concluded that those cutoffs were arbitrary given the known variability of echocardiographic measurement of LVEF and unresolved debate over whether thresholds should differ by sex, age, or ethnicity.

The lower limit of normal LVEF is now cited as approximately 53% for women and 52% for men, with slightly higher thresholds among individuals of Asian descent, reinforcing that no single number applies uniformly.

The new document therefore collapses the classification into three clinically actionable groups: reduced, preserved, and improved ejection fraction, without anchoring to a specific numeric boundary.

Figure 1 · HF Trajectory Across Stages

Stage AAt risk

Stage BPre-HF

Stage CSymptomatic HF

Stage DAdvanced HF

Improvement
(LVEF rises, abnormalities persist)

Remission
(normalized LVEF, minimal symptoms)

Recovery
(sustained normalization — minority)

Reframing Cause: Eighteen Pathogenic Groups Instead of Two

Clinical practice has long sorted heart failure into just ischemic and nonischemic cardiomyopathy, a split the committee says omits the treatable causes of dilated and hypertrophic disease.

A patient whose underlying cause is cardiac amyloidosis, for instance, benefits from disease-targeted therapy well beyond standard heart failure management.

The new framework proposes a pathogenic classification independent of ejection fraction, spanning ischemic, hypertensive, valvular, arrhythmia-related, infiltrative, infective, inflammatory, toxic, heritable, pericardial, metabolic and nutritional, pregnancy-related, stress-induced, pulmonary or right-sided, congenital, high-output, other, and idiopathic causes.

The intent is to standardize how causes are recorded in registries and trials, since the same patient population can otherwise be labeled inconsistently across studies.

Table 1 · Stages in the Development and Progression of HF

Stage	Definition
A — At risk	Hypertension, atherosclerotic disease, diabetes, obesity, cardiotoxin exposure, or family history of cardiomyopathy, without symptoms, structural change, or elevated biomarkers.
B — Pre-HF	Structural or functional cardiac abnormality, or elevated natriuretic peptide or troponin, without current or prior symptoms.
C — HF	Current or prior symptoms or signs caused by a structural or functional cardiac abnormality.
D — Advanced HF	Severe symptoms at rest or minimal exertion, recurrent hospitalization despite guideline-directed therapy, or need for inotropes, mechanical support, transplantation, or palliative care.

HF with Improved Ejection Fraction Is Not a Cure

Patients whose previously reduced LVEF rises or normalizes on therapy are classified as HF with improved ejection fraction, a category first formalized in the 2022 heart failure guideline.

The document is explicit that improvement in EF does not equal disease resolution, and these patients remain at risk for recurrent left ventricular dysfunction, hospitalization, and sudden cardiac death.

Once a diagnosis of symptomatic heart failure is established, the individual is generally considered to carry that diagnosis permanently, even if the clinical picture improves substantially.

Practically, this means continued guideline-directed medical therapy and longitudinal surveillance rather than a taper toward discontinuation once an echocardiogram looks reassuring.

A related but distinct state, HF in remission, applies to select asymptomatic patients with normalized LVEF and stable biomarkers, while true recovery with sustained normalization of structure, function, and symptoms is reached by only a minority.

Worsening HF and Decompensated HF Are Now Distinguished

The consensus separates worsening HF, a progressive deterioration in symptoms or signs in a patient with an established diagnosis, from new-onset presentations or symptom flares driven by unrelated events such as infection or nonadherence.

Decompensated HF is defined more narrowly as the point at which treatment intensification is required, commonly an increase in diuretic dose, addition of combination diuretic therapy, or escalation to advanced interventions.

The distinction matters for documentation and for trial eligibility, since decompensation implies a treatment threshold rather than simply a worse-feeling patient.

Recognizing HF Mimics

The document devotes explicit attention to conditions that resemble heart failure without being pathophysiologically driven by myocardial neurohormonal activation.

Chronic kidney disease, third-trimester pregnancy, and obesity with deconditioning can all produce dyspnea, edema, and exertional limitation that mimic HF, sometimes accompanied by falsely reassuring natriuretic peptide levels.

Roughly half of the heart failure population across the ejection-fraction spectrum has coexisting coronary disease, and myocardial ischemia itself can serve as a mimic, a comorbid driver, or a trigger of decompensation.

Geography Still Shapes Cause

Ischemic heart disease accounts for more than half of HF cases across Western high-income and Eastern European regions but under 10% in sub-Saharan Africa, where hypertensive heart disease predominates instead.

Chagas disease remains a leading cause in parts of Latin America, while chronic obstructive pulmonary disease contributes disproportionately to HF prevalence in South and East Asia.

The committee also flags a near-absence of sub-Saharan African participants in major heart failure trials, a gap that limits how confidently global guidance can be generalized.

Figure 2 · Leading Contributors to HF Prevalence by Region (Illustrative, Global Burden of Disease-Derived)

50%+

Ischemic heart disease
Western / E. Europe

33%

Hypertensive disease
Sub-Saharan Africa

38%

COPD-related
South Asia

16%

Alcoholic CM
Eastern Europe

<10%

Ischemic disease
Sub-Saharan Africa

The GDMT and Company Landscape

None of the four pillars of guideline-directed medical therapy change under the new definition, but the reclassification affects which patients trial sponsors and payers consider eligible for these agents.

For physician-investors tracking the space, the table below summarizes representative agents, current approximate cash pricing, and the companies behind them.

Table 2 · Representative GDMT Agents and Market Context

Class / Agent	Brand	Approx. Cash Price (30-day)	Company (Ticker)
ARNI — sacubitril/valsartan	Entresto	~$600–700 brand; generic ~$45–90 with discount card; Medicare Part D negotiated ~$295	Novartis (NVS)
SGLT2 inhibitor — dapagliflozin	Farxiga	~$530–780 brand; GoodRx cash ~$288; generic available	AstraZeneca (AZN)
SGLT2 inhibitor — empagliflozin	Jardiance	~$360–830 brand; no generic; copay card as low as $0	Boehringer Ingelheim (private) / Eli Lilly (LLY)
Nonsteroidal MRA — finerenone	Kerendia	~$550–600 brand; manufacturer copay assistance available	Bayer (BAYRY)
Steroidal MRA — spironolactone	generic (Aldactone)	<$15 generic	Multiple generic manufacturers

Pricing is a snapshot subject to change, and it reflects list or cash pricing rather than what any individual patient pays after insurance, rebates, or Medicare Part D redesign under the Inflation Reduction Act.

This is general financial education, not personalized investment advice, and analyst views on any of these names can shift quickly around earnings and pipeline readouts.

What Actually Changes at the Bedside

Staging from stage A through stage D is unchanged, so risk-factor counseling and pre-HF surveillance workflows remain valid as written.

What changes is the language used when documenting ejection-fraction category and cause, favoring the simplified three-group EF framework and the expanded eighteen-category cause list over the old ischemic-versus-nonischemic shorthand.

Clinicians involved in trial screening or registry data entry should expect case-report forms to migrate toward this vocabulary over the next several guideline cycles.

Case Vignette

A 68-year-old with a history of anterior myocardial infarction and an LVEF that improved from 30% to 46% on quadruple guideline-directed therapy is told by a well-meaning relative that they are "cured."

Applying the second universal definition, this patient is correctly classified as HF with improved ejection fraction, not as a patient in remission or recovery, since residual scar and biomarker elevation persist.

The clinical implication is continuation of all four GDMT pillars, periodic re-imaging, and counseling that the diagnosis of heart failure remains permanent despite the reassuring echocardiogram.

Bottom Line

The second universal definition of heart failure moves away from rigid LVEF cutoffs toward three clinically actionable phenotypes, expands cause classification from two categories to eighteen, and reinforces that improvement in ejection fraction is not equivalent to cure.

Staging (A through D) and the core four-pillar GDMT approach are unchanged, but documentation language, trial eligibility criteria, and registry data fields are likely to evolve toward this new framework over time.

References

1. AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure. Global Heart, 2026.
2. Second Universal Definition of HF Focuses on Phenotypes and Etiology. TCTMD, July 2026.
3. Universal Definition and Classification of Heart Failure: A Step in the Right Direction. American College of Cardiology, 2021.
4. Entresto Pricing and Savings. GoodRx, accessed 2026.
5. Farxiga vs. Jardiance: Comparing SGLT2 Inhibitors. GoodRx, 2026.

Disclaimer: This article is intended for physician education and general clinical discussion; it does not constitute individualized medical advice and should not replace clinical judgment or current society guidelines. Drug pricing and company information are provided for general financial education only, not as personalized investment advice; pricing is time-sensitive and subject to change, and past performance of any security does not predict future results. Consult a licensed financial advisor before making investment decisions.

Antiplatelet Therapy in 2026: What the New ACC Scientific Statement Changes for Practice

A synthesis of the new consensus document — and what it means for prescribing, deprescribing, and portfolios.

Physician Education & Market Perspective

A new 2026 ACC scientific statement on antiplatelet therapy pulls together, for the first time, guidance that had been scattered across separate acute coronary syndrome, chronic coronary disease, stroke, and peripheral artery disease documents.

The writing committee's stated goal was to give clinicians one framework for the ischemia-versus-bleeding tradeoff that now spans a patient's entire cardiovascular life, not just a single index event.

The single biggest practical shift is a growing comfort with shorter dual antiplatelet therapy courses followed by potent P2Y12 inhibitor monotherapy, rather than the traditional twelve months of combined aspirin and a P2Y12 agent.

Below is a distillation of the actionable changes, paired with the drug and device economics that matter to a physician-investor audience.

Case Vignette

A 68-year-old man is admitted with a non-ST-elevation myocardial infarction and undergoes drug-eluting stent placement to a single mid-vessel lesion.

He has no history of prior bleeding, a hemoglobin of 14 g/dL, and an estimated glomerular filtration rate of 68 mL/min, placing him at low bleeding risk by ARC-HBR criteria.

Under the new statement, a reasonable strategy is aspirin plus ticagrelor for one to three months, followed by ticagrelor monotherapy, rather than a fixed twelve-month dual-therapy course.

If he were instead 78 years old with a recent gastrointestinal bleed, the same statement would steer toward clopidogrel-based dual therapy with earlier deescalation to protect against hemorrhage.

Aspirin for Primary Prevention: A Narrower Lane

The statement reaffirms that routine aspirin for primary prevention in unselected adults is no longer supported, largely because background statin therapy already does much of the protective work aspirin once provided.

Low-dose aspirin may still be reasonable for adults 40 to 70 years old who carry a genuinely elevated ischemic risk and a low bleeding risk, but routine use past age 70 should be avoided.

A meta-analysis of thirteen large trials found a modest cardiovascular benefit (hazard ratio 0.89) offset by a 43% relative increase in major bleeding, with a number needed to harm of 880 for intracranial hemorrhage.

Coronary artery calcium scoring and lipoprotein(a) measurement can help identify the subset of patients in whom the benefit-risk ratio still favors aspirin.

P2Y12 Choice After PCI: Prasugrel's Case Strengthens

For acute coronary syndrome treated with PCI, prasugrel and ticagrelor remain preferred over clopidogrel, but the statement now leans further toward prasugrel where there is no contraindication.

Head-to-head data from ISAR-REACT 5 and the newer TUXEDO-2 trial, reported at the 2025 AHA sessions, both showed lower rates of death, MI, or stroke with prasugrel compared with ticagrelor, without a matching increase in bleeding.

Clopidogrel is still preferred in patients over 75 years old, in those at high bleeding risk, or where cost and access make the more potent agents impractical.

Ischemic risk falls sharply in the first month after an acute event while bleeding risk declines more gradually — the rationale for shifting from dual therapy to P2Y12 monotherapy at one to three months rather than waiting a full year.

Duration of DAPT: The Default Is Shrinking

For chronic coronary disease treated with PCI, six months of aspirin plus clopidogrel remains the default, but one to three months followed by P2Y12 monotherapy is now an accepted alternative in lower-risk patients.

For acute coronary syndrome, twelve months of dual therapy is still the baseline, yet shortened courses of one to three months followed by ticagrelor or prasugrel monotherapy are increasingly supported by trial data such as TWILIGHT, TICO, and TARGET-FIRST.

Clopidogrel-based shortened regimens have not shown the same safety margin; STOPDAPT-2 ACS found a trend toward more ischemic events when clopidogrel monotherapy followed only one to two months of dual therapy.

Very early aspirin withdrawal — within days rather than weeks — has also underperformed, as shown in the NEOMINDSET trial, so the deescalation window matters as much as the destination drug.

Table 1. Default DAPT Duration by Clinical Scenario (2026 ACC Statement)

Clinical Setting	Default Duration	Accepted Shortened Strategy	Preferred Agent(s)
Chronic coronary disease + PCI	6 months	1–3 months, then P2Y12 monotherapy	Clopidogrel; ticagrelor/prasugrel if low bleeding risk
Acute coronary syndrome + PCI	12 months	1–3 months, then P2Y12 monotherapy	Ticagrelor or prasugrel
PAD, post-revascularization	1–6 months	≤1 month before surgical bypass	Clopidogrel or ticagrelor
Minor stroke / high-risk TIA	21 days	Not applicable — fixed short course	Aspirin + clopidogrel
CABG (isolated)	Aspirin monotherapy	DAPT only if high graft-failure risk	Aspirin; clopidogrel alternative

Beyond One Year: Clopidogrel Monotherapy Gains Ground

Perhaps the most striking shift in the document is its treatment of long-term secondary prevention beyond the first year after an event.

Emerging data, reinforced by ten-year follow-up of the HOST-EXAM trial, suggest that clopidogrel monotherapy may offer better ischemic protection with similar or lower bleeding than aspirin monotherapy for chronic coronary disease.

For higher-risk patients with stable coronary or peripheral disease and no prior major bleeding or stroke, low-dose rivaroxaban 2.5 mg twice daily added to aspirin 81 mg daily remains an option, based on the COMPASS trial's reduction in cardiovascular death and total mortality.

Adding a full-dose direct oral anticoagulant to dual antiplatelet therapy, by contrast, has repeatedly produced excess bleeding without proportionate ischemic benefit across APPRAISE-2, ATLAS ACS 2-TIMI 51, and GEMINI-ACS-1.

Four distinct receptor pathways converge on platelet activation; aspirin and P2Y12 inhibitors act on separate pathways, which is why their combination (DAPT) produces additive platelet inhibition.

Drug and Device Economics for the Physician-Investor

Generic clopidogrel now costs as little as $4.50 a month with a GoodRx coupon, which helps explain its durability as the default agent whenever cost, adherence, or bleeding risk favor a less potent option.

Ticagrelor, sold as brand-name Brilinta by AstraZeneca NASDAQ: AZN, now faces generic competition; brand-name 90 mg tablets still run about $462 for a 30-day supply, while generic ticagrelor is available for roughly $23 to $30 with a coupon.

Prasugrel, marketed as Effient by Eli Lilly NYSE: LLY and co-developed with Daiichi Sankyo, is now generically available for about $14 to $20 a month with a coupon, down from several hundred dollars for the brand.

Rivaroxaban, sold as Xarelto by Bayer OTC: BAYRY in partnership with Johnson & Johnson in the United States, has a generic-available 2.5 mg dose priced around $30 with a GoodRx coupon, versus roughly $520 at retail.

Table 2. Antiplatelet and Adjunctive Antithrombotic Agents: Clinical and Market Snapshot

Generic (Brand)	Class	Manufacturer / Ticker	Typical Monthly Cash Price*	Analyst Consensus
Clopidogrel (Plavix)	P2Y12 inhibitor	Generic; originator Sanofi/BMS	~$4.50–$10	N/A (generic)
Ticagrelor (Brilinta)	P2Y12 inhibitor	AstraZeneca AZN	~$23–$30 (generic); ~$462 (brand)	Strong Buy, ~$224 PT
Prasugrel (Effient)	P2Y12 inhibitor	Eli Lilly LLY / Daiichi Sankyo	~$14–$20 (generic)	Buy, ~$1,216 PT
Rivaroxaban (Xarelto)	Factor Xa inhibitor	Bayer BAYRY / J&J	~$30 (2.5 mg generic); ~$520 (brand)	Moderate Buy, ~$12–$14 PT

*Cash prices reflect GoodRx-listed discounts as of early July 2026 and vary by pharmacy and location; insured patients typically pay less.

Special Populations in Brief

In peripheral artery disease, adding low-dose rivaroxaban to aspirin after revascularization reduces major adverse limb events, per the VOYAGER-PAD trial, particularly in patients with prior amputation or polyvascular disease.

In minor ischemic stroke or high-risk TIA, aspirin plus clopidogrel for 21 days followed by monotherapy reduces early recurrent stroke without the bleeding penalty seen with longer dual courses.

Triple therapy combining oral anticoagulation with dual antiplatelet therapy should be avoided whenever possible; the statement favors dropping aspirin within one month of PCI in patients who need an anticoagulant, leaving a P2Y12 inhibitor and a direct oral anticoagulant as the long-term combination.

Bottom Line

The 2026 ACC statement pushes practice toward shorter dual antiplatelet courses followed by potent P2Y12 monotherapy, a narrower and more selective role for aspirin in primary prevention, and a growing preference for clopidogrel monotherapy over aspirin monotherapy beyond the first year after a coronary event.

Genotype-guided or platelet-function-guided deescalation remains optional rather than mandatory, and unguided switching at one month after ACS-PCI appears similarly safe in the available trials.

From an investment standpoint, the shift toward shorter branded P2Y12 exposure and toward generic clopidogrel and rivaroxaban has modest read-through for volume-driven generics manufacturers, while AstraZeneca and Eli Lilly's franchise durability increasingly depends on newer indications and pipeline assets rather than legacy antiplatelet volume.

This content is for physician education only and does not constitute individualized clinical or investment advice; treatment decisions should be individualized, and any securities discussion should be verified against current company disclosures before acting.

References

1. Kumbhani DJ, et al. Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease: 2026 ACC Scientific Statement. JACC.
2. American College of Cardiology. Guidelines and Clinical Policy document library.
3. TCTMD. Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD (TUXEDO-2).
4. GoodRx. Clopidogrel pricing and savings information.
5. GoodRx. Brilinta (ticagrelor) pricing and savings information.
6. GoodRx. Prasugrel (Effient) pricing and savings information.
7. GoodRx. Xarelto (rivaroxaban) pricing and savings information.
8. StockAnalysis.com. AstraZeneca PLC (AZN) financial data.
9. StockAnalysis.com. Eli Lilly and Company (LLY) financial data.
10. StockAnalysis.com. Bayer Aktiengesellschaft (BAYRY) financial data.

This article is intended for physician education and does not constitute clinical practice guidance for any individual patient; treatment decisions require individualized assessment of ischemic and bleeding risk. Ticker symbols, pricing, and analyst data are provided for general informational and educational purposes only, are not investment advice, and should be independently verified; the author is not a licensed financial advisor. Drug pricing reflects publicly listed cash/discount prices at the time of writing and is subject to change.

Cardiology Monthly Roundup — June 2026

June 2026 in Cardiology: TAVI's Decade Mark, a New CKM Guideline, and a Gene-Editing First

A synthesis of the month's highest-yield structural, preventive, and antiplatelet news for practicing cardiologists and physician-investors.

Overview

June is traditionally a quieter month on the conference calendar than May, yet the past four weeks produced an unusually dense cluster of practice-relevant data.

Roughly half of the most-read stories from the period trace back to New York Valves 2026, where transcatheter aortic valve implantation (TAVI) durability, futility, and reimbursement all took center stage.

Beyond the valve world, a first-ever cardiovascular-kidney-metabolic (CKM) syndrome guideline, an early but genuinely novel gene-editing therapy for LDL lowering, a practice-shaping antiplatelet meta-analysis, and a small but intriguing vitamin K trial rounded out the list.

This roundup pulls the clinical threads together and flags where physician-investors may want to keep an eye on the corporate side of the story.

TAVI at 10 Years: Reassuring, With Caveats

Two analyses published in the June 16, 2026 issue of JACC gave cardiologists their longest look yet at TAVI versus surgical aortic valve replacement (SAVR).

In the overall 10-year cohort, all-cause mortality was numerically higher after TAVI than SAVR (86.1% vs 82.8%; HR 1.13), a difference attributed largely to the older, higher-risk population that received TAVI in earlier device generations.

Notably, a propensity-matched comparison restricted to the third-generation Sapien 3 valve (Edwards Lifesciences) against contemporary SAVR patients from PARTNER 2A did not show this gap, suggesting that modern valve design and CT-based procedural planning have narrowed the durability question considerably.

Follow-up completeness remains an important limitation, since only about 62% of TAVI patients and 54% of SAVR patients had directly reported 10-year data before a supplemental vital-status sweep filled in the rest.

Extending TAVI to Asymptomatic Disease

The most closely watched update at New York Valves 2026 was the 5-year analysis of the EARLY TAVR trial, which randomized patients with asymptomatic severe aortic stenosis to prompt transfemoral TAVI or clinical surveillance.

Death and stroke curves were essentially identical between arms through the first 2 years, reinforcing the trial's original conclusion that early intervention carries no early safety penalty.

That evidence base is already reshaping coverage policy: the Centers for Medicare & Medicaid Services (CMS) has proposed expanding national TAVI coverage to asymptomatic patients, with a final ruling expected in September 2026.

The proposed decision memo would also allow triaging by chart review and give heart teams greater flexibility in documenting shared decision-making, a change that has direct workflow implications for structural programs.

This coverage expansion follows a May 2025 FDA approval of an expanded Sapien 3 indication for asymptomatic disease, a request originally submitted by Edwards Lifesciences as the EARLY TAVR trial sponsor.

Durability Through 7 Years in Low-Risk Patients

A separate late-breaking session paired new randomized and real-world data showing TAVI durability out to 7 years in low-surgical-risk patients treated with balloon-expandable valves.

Investigators described the findings as reassuring for current practice, while cautioning that even longer follow-up is still needed before extending TAVI further down the age and risk spectrum.

Complementary presentations covered the self-expanding Evolut platform (Medtronic) and small-annulus outcomes with the Navitor valve (Abbott), broadening the durability picture beyond a single device family.

Weighing Futility After a "Successful" TAVI

Not every headline was reassuring: new registry data from TRITAVI found that roughly 1 in 25 patients died between 30 days and 12 months after an otherwise uncomplicated TAVI.

Most of these deaths were noncardiovascular, and COPD, atrial fibrillation, severe chronic kidney disease, and reduced ejection fraction were the strongest independent predictors.

Investigators framed the finding as a useful, if sobering, data point for shared decision-making conversations about futility rather than a reason to withhold treatment broadly.

Figure 1. Unadjusted 10-year mortality, overall TAVI vs SAVR cohort (JACC, June 16, 2026). The gap narrowed substantially in a propensity-matched Sapien 3-only comparison.

2017–2024

EARLY TAVR enrolls 901 asymptomatic severe AS patients

2024

Primary results published; changes perception of asymptomatic AS management

May 2025

FDA expands Sapien 3 indication to asymptomatic AS

Jun 2026

5-year data show sustained death/stroke equivalence at 2 years

Sep 2026*

CMS final coverage ruling expected

Figure 2. Pathway from trial to coverage policy for asymptomatic severe AS. *Projected date per proposed CMS decision memo.

TAVI Headlines at a Glance

Story	Key Metric	Practice Signal
10-year TAVI vs SAVR	86.1% vs 82.8% mortality (HR 1.13)	Gap narrows with modern Sapien 3-era practice
EARLY TAVR, 5-year	Equivalent death/stroke at 2 years	Supports earlier intervention in asymptomatic AS
7-year durability, low risk	Reassuring across RCT + real-world data	Longer follow-up still needed
TRITAVI registry	4% die between 30 days–12 months	Informs futility, shared decision-making
CMS coverage proposal	Decision expected September 2026	Would expand access, ease heart-team documentation burden

First-Ever CKM Syndrome Guideline

Away from the valve, the AHA and ACC, together with the American Diabetes Association and American Society of Nephrology, issued the first comprehensive guideline on cardiovascular-kidney-metabolic (CKM) syndrome.

The document introduces a four-stage framework, ranging from isolated risk factors (Stage 1) to established cardiovascular disease with concurrent metabolic or kidney disease (Stage 4).

Central to the guideline is broader use of the PREVENT risk equations, which incorporate kidney and metabolic variables to estimate 10- and 30-year cardiovascular risk more precisely than legacy pooled-cohort tools.

Nearly 90% of US adults have at least one CKM risk factor, underscoring how broadly this staging system is likely to apply in routine outpatient cardiology practice.

For heart failure with mildly reduced or preserved ejection fraction, the guideline reiterates SGLT2 inhibitors as first-line therapy and supports layering GLP-1–based agents in patients with obesity, alongside consideration of nonsteroidal mineralocorticoid receptor antagonists in type 2 diabetes with chronic kidney disease.

A Gene-Editing First for PCSK9

In lipid-lowering news, interim phase I data from the Heart-2 trial showed that a single infusion of the in vivo base-editing therapy VERVE-102 reduced PCSK9 protein levels by up to 88% and LDL cholesterol by up to 62% (roughly a 78 mg/dL absolute reduction) at the highest dose.

The therapy uses a GalNAc-lipid nanoparticle carrier to deliver a base-editing complex to hepatocytes, permanently inactivating the PCSK9 gene through a single adenine-to-guanine DNA edit.

Tolerability was generally favorable, with infusion-related reactions in about 20% of patients and one serious but self-limited case of aspiration pneumonitis.

On the corporate side, Verve Therapeutics became a wholly owned subsidiary of Eli Lilly and Company in July 2025, so the former Nasdaq ticker VERV has been delisted and the PCSK9 gene-editing program now sits inside Lilly's broader cardiometabolic pipeline.

A phase II study of VERVE-102 is expected to begin enrolling later in 2026, with familial hypercholesterolemia and premature coronary disease as the initial target populations.

Prasugrel Edges Out Rivals After PCI

A new meta-analysis published in JAMA Cardiology and summarized by TCTMD found that among the three major oral P2Y12 inhibitors, prasugrel offered the best overall balance of efficacy and safety after PCI.

Compared with clopidogrel, prasugrel lowered the risk of MACE, myocardial infarction, and stent thrombosis without a corresponding increase in major bleeding.

Compared with ticagrelor, prasugrel again showed lower MACE, MI, and stent thrombosis, while ticagrelor carried higher rates of major bleeding and intracranial hemorrhage.

These findings echo two prior randomized trials, ISAR-REACT 5 and TUXEDO-2, both of which leaned toward a prasugrel advantage over ticagrelor in appropriately selected post-PCI patients.

Vitamin K and Coronary Calcium: An Intriguing Signal

Finally, the Dutch VitaK-CAC trial randomized 180 patients with mild coronary calcification (Agatston scores 50–400) to daily menaquinone-7 (MK-7) supplementation or placebo.

Over 2 years, CAC score progression was significantly slower in the MK-7 group, and levels of dp-ucMGP, a vitamin K-dependent protein that inhibits vascular calcification, rose less steeply in that arm.

The annualized increase in CAC score was reduced by an estimated 19 Agatston units with MK-7 treatment relative to placebo.

Experts interviewed for the coverage were careful to note that the clinical significance of a smaller CAC increase remains uncertain, and that routine MK-7 supplementation is not yet ready for prime time outside of further confirmatory trials.

Drugs, Devices, and Companies in the News

Agent / Device	Generic / Brand	Company (Ticker)	Notes
TAVI valve	Sapien 3 (balloon-expandable)	Edwards Lifesciences (NYSE: EW)	EARLY TAVR sponsor; ~$85–95/share range, consensus Buy
TAVI valve	Evolut (self-expanding)	Medtronic (NYSE: MDT)	~$80–90/share range, consensus Buy
Structural heart / LAAO	Watchman; MiRus valve stake	Boston Scientific (NYSE: BSX)	Shares pulled back on Watchman guidance cuts; still consensus Buy
VERVE-102 (gene editing)	In vivo PCSK9 base editor	Eli Lilly (NYSE: LLY)	Former Verve Therapeutics (VERV) program; VERV delisted July 2025
P2Y12 inhibitor	Prasugrel (Effient), generic available	Multiple generic manufacturers	Off-patent; lowest-cost of the potent P2Y12 agents
P2Y12 inhibitor	Ticagrelor (Brilinta)	AstraZeneca (Nasdaq: AZN)	Twice-daily dosing; higher bleeding signal in new meta-analysis
Vitamin K2 supplement	Menaquinone-7 (MenaQ7)	Gnosis by Lesaffre	Privately held; over-the-counter supplement, not FDA-regulated as a drug

Case Vignette

A 74-year-old man with hypertension, type 2 diabetes, and stage 3 chronic kidney disease is found to have severe aortic stenosis on a surveillance echocardiogram, without exertional symptoms on careful questioning.

He asks whether he should simply be monitored until symptoms develop, as his neighbor was advised a decade ago.

Applying the 5-year EARLY TAVR data, the cardiologist explains that early transfemoral TAVI has shown no penalty in death or stroke compared with surveillance through at least 2 years, and that pending CMS coverage changes may soon remove some of the administrative barriers to earlier intervention.

At the same visit, his CKM syndrome stage is formally documented as Stage 3, prompting initiation of an SGLT2 inhibitor and calculation of his 10-year PREVENT risk score to guide further risk-factor management.

Bottom Line

TAVI's evidence base continues to mature in two directions at once: reassuring long-term durability data at 7 and 10 years, and expanding indications into asymptomatic disease that will likely become easier to act on once CMS finalizes its coverage decision.

The new CKM syndrome guideline gives cardiologists a shared staging language with endocrinology and nephrology, anchored by the PREVENT risk equations.

VERVE-102 remains an early but genuinely novel proof of concept for one-time gene-editing therapy in lipid management, now under Eli Lilly's umbrella rather than as a standalone public company.

For routine post-PCI antiplatelet selection, the new meta-analysis adds further support for prasugrel as a first-choice potent P2Y12 inhibitor in patients without a specific contraindication.

Disclaimer: This article is intended for physician education and does not constitute individualized clinical guidance; treatment decisions should be based on current guidelines and individual patient assessment. Content referencing publicly traded companies is provided for general financial education only, does not constitute investment advice, and should not be relied upon for trading decisions; approximate share prices and analyst ratings are time-sensitive snapshots that may have changed since publication, and past performance does not guarantee future results. The author is not a licensed financial advisor.

References

1. TCTMD. New 10-Year TAVI Data Generally 'Reassuring' But Highlight Challenges.
2. TCTMD. AHA/ACC Release First Comprehensive Guideline on CKM Syndrome.
3. TCTMD. Gene-Editing Therapy Safely Lowers PCSK9, LDL Cholesterol in Phase I: Heart-2.
4. TCTMD. Meta-analysis: Prasugrel the Best P2Y12 Inhibitor After PCI?
5. TCTMD. EARLY TAVR: 5-Year Data Still Support TAVI Over Surveillance in Asymptomatic AS.
6. TCTMD. Following Successful TAVI, 4% Die Between 1 and 12 Months: TRITAVI.
7. TCTMD. What's Going to Be Hot at New York Valves 2026.
8. TCTMD. Vitamin K Supplementation May Reduce Coronary Calcification: VitaK-CAC.
9. TCTMD. CMS Proposes Expanding TAVI Coverage to Asymptomatic Patients.
10. American College of Cardiology. First-Ever Guideline Addresses CKM Syndrome.